(USPH) US Physicalrapy - Ratings and Ratios
Physical Therapy, Occupational Therapy, Rehabilitation
USPH EPS (Earnings per Share)
USPH Revenue
Description: USPH US Physicalrapy
US Physical Therapy Inc (NYSE:USPH) is a healthcare company operating in the Health Care Facilities sub-industry. The companys financial performance can be evaluated through its income statement, particularly the yearly Income Tax Expense, which is a crucial component in determining its net earnings.
To assess the companys valuation, we can look at its Market Cap of $1.33B, indicating a relatively moderate size. The Price-to-Earnings (P/E) ratio of 38.29 and Forward P/E of 36.23 suggest that the stock is trading at a premium, potentially due to expected growth. The Return on Equity (RoE) of 6.43% is relatively modest, indicating that the company may not be generating exceptionally high returns on shareholder equity.
Key economic drivers for USPH include the demand for physical therapy services, reimbursement rates from payers such as Medicare and private insurance, and the overall healthcare spending in the US. The companys performance is also influenced by its ability to manage costs, including labor and facility expenses. Key Performance Indicators (KPIs) to monitor include revenue growth, same-store sales growth, and operating margin expansion.
From a trading perspective, USPHs stock has shown volatility, with a Beta of 1.448, indicating that it tends to move more than the overall market. The stocks current price is near its 52-week high, suggesting strong recent performance. To evaluate the stocks potential, we can analyze its moving averages, such as the SMA20, SMA50, and SMA200, which can provide insights into its trend and momentum.
USPH Stock Overview
| Market Cap in USD | 1,352m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 1992-05-28 |
USPH Stock Ratings
| Growth Rating | -8.03% |
| Fundamental | 62.6% |
| Dividend Rating | 69.0% |
| Return 12m vs S&P 500 | -3.18% |
| Analyst Rating | 4.14 of 5 |
USPH Dividends
| Dividend Yield 12m | 2.04% |
| Yield on Cost 5y | 2.24% |
| Annual Growth 5y | 53.14% |
| Payout Consistency | 92.0% |
| Payout Ratio | 71.9% |
USPH Growth Ratios
| Growth Correlation 3m | 59.5% |
| Growth Correlation 12m | -34.2% |
| Growth Correlation 5y | -52.2% |
| CAGR 5y | 6.35% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.14 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.31 |
| Sharpe Ratio 12m | -0.83 |
| Alpha | -4.90 |
| Beta | 1.479 |
| Volatility | 29.57% |
| Current Volume | 153.9k |
| Average Volume 20d | 147.4k |
| Stop Loss | 84 (-4.2%) |
| Signal | -0.42 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (31.7m TTM) > 0 and > 6% of Revenue (6% = 39.9m TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -1.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.26% (prev 15.07%; Δ -11.81pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 71.7m > Net Income 31.7m (YES >=105%, WARN >=100%) |
| Net Debt (119.7m) to EBITDA (101.4m) ratio: 1.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.2m) change vs 12m ago 0.83% (target <= -2.0% for YES) |
| Gross Margin 20.37% (prev 18.64%; Δ 1.73pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 60.40% (prev 61.35%; Δ -0.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 9.06 (EBITDA TTM 101.4m / Interest Expense TTM 8.77m) >= 6 (WARN >= 3) |
Altman Z'' 1.86
| (A) 0.02 = (Total Current Assets 140.5m - Total Current Liabilities 118.8m) / Total Assets 1.18b |
| (B) 0.20 = Retained Earnings (Balance) 236.4m / Total Assets 1.18b |
| (C) 0.07 = EBIT TTM 79.4m / Avg Total Assets 1.10b |
| (D) 0.57 = Book Value of Equity 237.7m / Total Liabilities 414.0m |
| Total Rating: 1.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.55
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 3.75% = 1.87 |
| 3. FCF Margin 9.15% = 2.29 |
| 4. Debt/Equity 0.61 = 2.32 |
| 5. Debt/Ebitda 1.18 = 1.50 |
| 6. ROIC - WACC (= 0.11)% = 0.14 |
| 7. RoE 6.43% = 0.54 |
| 8. Rev. Trend 78.96% = 5.92 |
| 9. EPS Trend -40.59% = -2.03 |
What is the price of USPH shares?
Over the past week, the price has changed by -2.02%, over one month by +9.28%, over three months by +19.55% and over the past year by +9.52%.
Is US Physicalrapy a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of USPH is around 84.55 USD . This means that USPH is currently overvalued and has a potential downside of -3.61%.
Is USPH a buy, sell or hold?
- Strong Buy: 2
- Buy: 4
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the USPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 107 | 22% |
| Analysts Target Price | 107 | 22% |
| ValueRay Target Price | 95.1 | 8.4% |
Last update: 2025-10-04 04:01
USPH Fundamental Data Overview
P/E Trailing = 38.8384
P/E Forward = 31.5457
P/S = 1.8724
P/B = 2.6476
P/EG = 2.9832
Beta = 1.479
Revenue TTM = 665.2m USD
EBIT TTM = 79.4m USD
EBITDA TTM = 101.4m USD
Long Term Debt = 151.9m USD (from longTermDebt, last quarter)
Short Term Debt = 49.2m USD (from shortTermDebt, last quarter)
Debt = 305.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 119.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.62b USD (1.35b + Debt 305.4m - CCE 34.1m)
Interest Coverage Ratio = 9.06 (Ebit TTM 79.4m / Interest Expense TTM 8.77m)
FCF Yield = 3.75% (FCF TTM 60.9m / Enterprise Value 1.62b)
FCF Margin = 9.15% (FCF TTM 60.9m / Revenue TTM 665.2m)
Net Margin = 4.76% (Net Income TTM 31.7m / Revenue TTM 665.2m)
Gross Margin = 20.37% ((Revenue TTM 665.2m - Cost of Revenue TTM 529.7m) / Revenue TTM)
Gross Margin QoQ = 25.35% (prev 20.36%)
Tobins Q-Ratio = 1.38 (Enterprise Value 1.62b / Total Assets 1.18b)
Interest Expense / Debt = 0.79% (Interest Expense 2.42m / Debt 305.4m)
Taxrate = 21.78% (4.93m / 22.7m)
NOPAT = 62.1m (EBIT 79.4m * (1 - 21.78%))
Current Ratio = 1.18 (Total Current Assets 140.5m / Total Current Liabilities 118.8m)
Debt / Equity = 0.61 (Debt 305.4m / totalStockholderEquity, last quarter 500.8m)
Debt / EBITDA = 1.18 (Net Debt 119.7m / EBITDA 101.4m)
Debt / FCF = 1.97 (Net Debt 119.7m / FCF TTM 60.9m)
Total Stockholder Equity = 492.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.69% (Net Income 31.7m / Total Assets 1.18b)
RoE = 6.43% (Net Income TTM 31.7m / Total Stockholder Equity 492.4m)
RoCE = 12.32% (EBIT 79.4m / Capital Employed (Equity 492.4m + L.T.Debt 151.9m))
RoIC = 9.58% (NOPAT 62.1m / Invested Capital 648.1m)
WACC = 9.47% (E(1.35b)/V(1.66b) * Re(11.47%) + D(305.4m)/V(1.66b) * Rd(0.79%) * (1-Tc(0.22)))
Discount Rate = 11.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.70%
[DCF Debug] Terminal Value 66.51% ; FCFE base≈63.9m ; Y1≈63.0m ; Y5≈65.1m
Fair Price DCF = 45.46 (DCF Value 691.1m / Shares Outstanding 15.2m; 5y FCF grow -2.19% → 3.0% )
EPS Correlation: -40.59 | EPS CAGR: -57.95% | SUE: -4.0 | # QB: 0
Revenue Correlation: 78.96 | Revenue CAGR: 6.08% | SUE: -2.62 | # QB: 0
Additional Sources for USPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle